{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T03:25:00Z","timestamp":1782703500185,"version":"3.54.5"},"reference-count":101,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2018,9,18]],"date-time":"2018-09-18T00:00:00Z","timestamp":1537228800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>T cell non-Hodgkin lymphoma (T-NHL) is a rare and heterogeneous group of neoplasms of the lymphoid system. With the exception of a few relatively indolent entities, T-NHL is typically aggressive, treatment resistant, and associated with poor prognosis. Relatively few options with proven clinical benefit are available for patients with relapsed or refractory disease. Immunotherapy has emerged as a promising treatment for the management of patients with hematological malignancies. The identification of tumor antigens has provided a large number of potential targets. Therefore, several monoclonal antibodies (alemtuzumab, SGN-30, brentuximab vedotin, and mogamulizumab), directed against tumor antigens, have been investigated in different subtypes of T-NHL. In addition to targeting antigens involved in cancer cell physiology, antibodies can stimulate immune effector functions or counteract immunosuppressive mechanisms. Chimeric antigen receptor (CAR)-T cells directed against CD30 and immune checkpoint inhibitors are currently being investigated in clinical trials. In this review, we summarize the currently available clinical evidence for immunotherapy in T-NHL, focusing on the results of clinical trials using first generation monoclonal antibodies, new immunotherapeutic agents, immune checkpoint inhibitors, and CAR-T cell therapies.<\/jats:p>","DOI":"10.3390\/cancers10090339","type":"journal-article","created":{"date-parts":[[2018,9,18]],"date-time":"2018-09-18T11:52:29Z","timestamp":1537271549000},"page":"339","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Current Immunotherapeutic Approaches in T Cell Non-Hodgkin Lymphomas"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2560-8488","authenticated-orcid":false,"given":"Teresa","family":"Poggio","sequence":"first","affiliation":[{"name":"Department of Hematology and Oncology, Medical Center, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany"},{"name":"Faculty of Biology, Albert Ludwigs University of Freiburg, 79104 Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justus","family":"Duyster","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Medical Center, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany"},{"name":"German Cancer Consortium (DKTK) Partner Site Freiburg, 79106 Freiburg, Germany"},{"name":"German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna L.","family":"Illert","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Medical Center, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany"},{"name":"German Cancer Consortium (DKTK) Partner Site Freiburg, 79106 Freiburg, Germany"},{"name":"German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2018,9,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21442","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the world health organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: Pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","article-title":"Who-eortc classification for cutaneous lymphomas","volume":"105","author":"Willemze","year":"2005","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1182\/blood-2008-10-184168","article-title":"Cutaneous lymphoma incidence patterns in the united states: A population-based study of 3884 cases","volume":"113","author":"Bradford","year":"2009","journal-title":"Blood"},{"key":"ref_6","first-page":"76","article-title":"Prognostic significance of T-cell phenotype in aggressive non-hodgkin\u2019s lymphomas. Groupe d\u2019etudes des lymphomes de l\u2019adulte (gela)","volume":"92","author":"Gisselbrecht","year":"1998","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"623924","DOI":"10.5402\/2011\/623924","article-title":"A systematic review and meta-analysis of front-line anthracycline-based chemotherapy regimens for peripheral T-cell lymphoma","volume":"2011","author":"Abouyabis","year":"2011","journal-title":"ISRN Hematol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"5458","DOI":"10.1200\/JCO.2007.11.9958","article-title":"Vcap-amp-vecp compared with biweekly chop for adult T-cell leukemia-lymphoma: Japan clinical oncology group study JCOG9801","volume":"25","author":"Tsukasaki","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1200\/JCO.2012.44.7524","article-title":"Survival of patients with peripheral T-cell lymphoma after first relapse or progression: Spectrum of disease and rare long-term survivors","volume":"31","author":"Mak","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0092-8674(02)00625-6","article-title":"Apoptosis: A link between cancer genetics and chemotherapy","volume":"108","author":"Johnstone","year":"2002","journal-title":"Cell"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1097\/00002820-199712000-00007","article-title":"Side effects of chop in the treatment of non-hodgkin\u2019s lymphoma","volume":"20","author":"Sitzia","year":"1997","journal-title":"Cancer Nurs."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1093\/annonc\/mdu443","article-title":"Peripheral T-cell lymphomas in a large us multicenter cohort: Prognostication in the modern era including impact of frontline therapy","volume":"25","author":"Abramson","year":"2014","journal-title":"Ann. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/bjh.13855","article-title":"A phase ii study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) alternating with pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): Final results from the T-cell consortium trial","volume":"172","author":"Advani","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/cncr.21971","article-title":"The risk of secondary malignancies over 30 years after the treatment of non-hodgkin lymphoma","volume":"107","author":"Tward","year":"2006","journal-title":"Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1093\/jnci\/87.7.524","article-title":"Bladder and kidney cancer following cyclophosphamide therapy for non-hodgkin\u2019s lymphoma","volume":"87","author":"Travis","year":"1995","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"398","DOI":"10.3324\/haematol.12120","article-title":"Secondary malignancies after treatment for indolent non-hodgkin\u2019s lymphoma: A 16-year follow-up study","volume":"93","author":"Sacchi","year":"2008","journal-title":"Haematologica"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1200\/JCO.2005.04.2200","article-title":"Risk of second malignancy after non-hodgkin\u2019s lymphoma: A british cohort study","volume":"24","author":"Mudie","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1200\/JCO.2007.14.6068","article-title":"Risk of subsequent solid tumors after non-hodgkin\u2019s lymphoma: Effect of diagnostic age and time since diagnosis","volume":"26","author":"Hemminki","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"4014","DOI":"10.1182\/blood-2007-08-106021","article-title":"Cause-specific mortality and second cancer incidence after non-hodgkin lymphoma: A report from the childhood cancer survivor study","volume":"111","author":"Bluhm","year":"2008","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1182\/blood-2003-04-1124","article-title":"Second cancers and late toxicities after treatment of aggressive non-hodgkin lymphoma with the acvbp regimen: A gela cohort study on 2837 patients","volume":"103","author":"Andre","year":"2004","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"122","DOI":"10.3816\/CLM.2005.n.038","article-title":"Late non-neoplastic events in patients with aggressive non-hodgkin\u2019s lymphoma in four randomized european organisation for research and treatment of cancer trials","volume":"6","author":"Moser","year":"2005","journal-title":"Clin. Lymphoma Myeloma"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nri2326","article-title":"Inhibitory b7-family molecules in the tumour microenvironment","volume":"8","author":"Zou","year":"2008","journal-title":"Nat. Rev. Immunol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1200\/JCO.2016.67.3467","article-title":"Programmed death-1 blockade with pembrolizumab in patients with classical hodgkin lymphoma after brentuximab vedotin failure","volume":"34","author":"Armand","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"Pd-1 blockade with nivolumab in relapsed or refractory hodgkin\u2019s lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","article-title":"The basic principles of chimeric antigen receptor design","volume":"3","author":"Sadelain","year":"2013","journal-title":"Cancer Discov."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T cells in refractory b-cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel car T-cell therapy in refractory large b-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing cd19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: A phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.1182\/blood-2002-09-2802","article-title":"Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides\/sezary syndrome","volume":"101","author":"Lundin","year":"2003","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1182\/blood-2003-10-3389","article-title":"A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas","volume":"103","author":"Enblad","year":"2004","journal-title":"Blood"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1111\/bjd.12690","article-title":"Long-term efficacy and safety of alemtuzumab in advanced primary cutaneous T-cell lymphomas","volume":"170","author":"Guitera","year":"2014","journal-title":"Br. J. Dermatol."},{"key":"ref_34","first-page":"702","article-title":"Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma","volume":"90","author":"Zinzani","year":"2005","journal-title":"Haematologica"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1007\/s10637-010-9523-2","article-title":"Dose modification of alemtuzumab in combination with dexamethasone, cytarabine, and cisplatin in patients with relapsed or refractory peripheral T-cell lymphoma: Analysis of efficacy and toxicity","volume":"30","author":"Kim","year":"2012","journal-title":"Investig. New Drugs"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00280-007-0469-9","article-title":"Alemtuzumab plus chop as front-line chemotherapy for patients with peripheral T-cell lymphomas: A phase ii study","volume":"60","author":"Kim","year":"2007","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1182\/blood-2007-02-074641","article-title":"Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: Results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial","volume":"110","author":"Gallamini","year":"2007","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1093\/annonc\/mdq635","article-title":"Intensified alemtuzumab-chop therapy for peripheral T-cell lymphoma","volume":"22","author":"Lugtenburg","year":"2011","journal-title":"Ann. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"6217","DOI":"10.1158\/1078-0432.CCR-09-0162","article-title":"A phase II study of SGN-30 in cutaneous anaplastic large cell lymphoma and related lymphoproliferative disorders","volume":"15","author":"Duvic","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1365-2141.2009.07740.x","article-title":"A phase II study of SGN-30 (anti-CD30 mAb) in hodgkin lymphoma or systemic anaplastic large cell lymphoma","volume":"146","author":"Leonard","year":"2009","journal-title":"Br. J. Haematol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","article-title":"Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: Results of a phase II study","volume":"30","author":"Pro","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1182\/blood-2017-05-780049","article-title":"Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma","volume":"130","author":"Pro","year":"2017","journal-title":"Blood"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1200\/JCO.2014.60.3969","article-title":"Phase II investigator-initiated study of brentuximab vedotin in mycosis fungoides and sezary syndrome with variable cd30 expression level: A multi-institution collaborative project","volume":"33","author":"Kim","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1182\/blood-2013-12-542142","article-title":"Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin","volume":"123","author":"Horwitz","year":"2014","journal-title":"Blood"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1200\/JCO.2013.54.2456","article-title":"Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: Results of a phase I study","volume":"32","author":"Fanale","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1182\/blood-2017-12-821009","article-title":"Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas","volume":"131","author":"Fanale","year":"2018","journal-title":"Blood"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0140-6736(17)31266-7","article-title":"Brentuximab vedotin or physician\u2019s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): An international, open-label, randomised, phase 3, multicentre trial","volume":"390","author":"Prince","year":"2017","journal-title":"Lancet"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1200\/JCO.2011.37.3472","article-title":"Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: A multicenter phase II study","volume":"30","author":"Ishida","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1182\/blood-2014-09-600924","article-title":"Phase 1\/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma","volume":"125","author":"Duvic","year":"2015","journal-title":"Blood"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1200\/JCO.2013.52.0924","article-title":"Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma","volume":"32","author":"Ogura","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1182\/blood.V130.Suppl_1.817.817","article-title":"Anti-CCR4 monoclonal antibody, mogamulizumab, demonstrates significant improvement in pfs compared to vorinostat in patients with previously treated cutaneous T-cell lymphoma (CTCL): Results from the phase III MAVORIC study","volume":"130","author":"Kim","year":"2017","journal-title":"Blood"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/(SICI)1096-9896(200004)190:5<613::AID-PATH559>3.0.CO;2-0","article-title":"Expression of the CD30 antigen in non-lymphoid tissues and cells","volume":"190","author":"Durkop","year":"2000","journal-title":"J. Pathol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/modpathol.2012.52","article-title":"EBV-positive diffuse large B-cell lymphoma of the elderly is an aggressive post-germinal center B-cell neoplasm characterized by prominent nuclear factor-kB activation","volume":"25","author":"Odqvist","year":"2012","journal-title":"Mod. Pathol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/299065a0","article-title":"Production of a monoclonal antibody specific for hodgkin and sternberg-reed cells of hodgkin\u2019s disease and a subset of normal lymphoid cells","volume":"299","author":"Schwab","year":"1982","journal-title":"Nature"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1182\/blood.V66.4.848.848","article-title":"The expression of the hodgkin\u2019s disease associated antigen ki-1 in reactive and neoplastic lymphoid tissue: Evidence that reed-sternberg cells and histiocytic malignancies are derived from activated lymphoid cells","volume":"66","author":"Stein","year":"1985","journal-title":"Blood"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.3892\/ol.2017.5592","article-title":"Prognostic significance of CD30 expression in nasal natural killer\/T-cell lymphoma","volume":"13","author":"Wang","year":"2017","journal-title":"Oncol. Lett."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"7063","DOI":"10.1158\/1078-0432.CCR-04-0789","article-title":"Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate","volume":"10","author":"Hamblett","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1440-1827.2007.02195.x","article-title":"Usefulness of flow cytometry for differential diagnosis of precursor and peripheral T-cell and NK-cell lymphomas: Analysis of 490 cases","volume":"58","author":"Karube","year":"2008","journal-title":"Pathol. Int."},{"key":"ref_59","first-page":"3625","article-title":"Clinical significance of CCR4 expression in adult T-cell leukemia\/lymphoma: Its close association with skin involvement and unfavorable outcome","volume":"9","author":"Ishida","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1309\/AJCP09OTJOYAVZZK","article-title":"Simplified flow cytometric assessment in mycosis fungoides and sezary syndrome","volume":"136","author":"Hristov","year":"2011","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"5494","DOI":"10.1158\/1078-0432.CCR-04-0371","article-title":"CXC chemokine receptor 3 and CC chemokine receptor 4 expression in T-cell and NK-cell lymphomas with special reference to clinicopathological significance for peripheral T-cell lymphoma, unspecified","volume":"10","author":"Ishida","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1182\/blood.V96.2.685.014k26_685_690","article-title":"Expression pattern of T-cell-associated chemokine receptors and their chemokines correlates with specific subtypes of T-cell non-hodgkin lymphoma","volume":"96","author":"Jones","year":"2000","journal-title":"Blood"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1182\/blood-2016-09-692541","article-title":"Angioimmunoblastic T-cell lymphoma: The many-faced lymphoma","volume":"129","author":"Lunning","year":"2017","journal-title":"Blood"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1182\/blood-2009-04-216671","article-title":"B7-H1 (PD-l1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders","volume":"114","author":"Wilcox","year":"2009","journal-title":"Blood"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/DAD.0b013e31821c35cb","article-title":"Expression patterns of the immunosuppressive proteins PD-1\/CD279 and PD-l1\/CD274 at different stages of cutaneous T-cell lymphoma\/mycosis fungoides","volume":"34","author":"Kantekure","year":"2012","journal-title":"Am. J. Dermatopathol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1158\/1078-0432.CCR-13-0855","article-title":"Pd-l1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies","volume":"19","author":"Chen","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/nature18294","article-title":"Aberrant PD-l1 expression through 3\u2032-UTR disruption in multiple cancers","volume":"534","author":"Kataoka","year":"2016","journal-title":"Nature"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1038\/leu.2017.103","article-title":"PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma","volume":"31","author":"Atsaves","year":"2017","journal-title":"Leukemia"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s13045-016-0341-7","article-title":"PD-l1 is upregulated by EBV-driven LMP1 through NF-kappaB pathway and correlates with poor prognosis in natural killer\/T-cell lymphoma","volume":"9","author":"Bi","year":"2016","journal-title":"J. Hematol. Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"33035","DOI":"10.18632\/oncotarget.8847","article-title":"High post-treatment serum levels of soluble programmed cell death ligand 1 predict early relapse and poor prognosis in extranodal NK\/T cell lymphoma patients","volume":"7","author":"Wang","year":"2016","journal-title":"Oncotarget"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s00428-016-2011-0","article-title":"Expression of programmed cell death ligand 1 (PD-l1) in advanced stage ebv-associated extranodal NK\/T cell lymphoma is associated with better prognosis","volume":"469","author":"Kim","year":"2016","journal-title":"Virchows Arch."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3960\/jslrt.17006","article-title":"Stat3 inhibitor abrogates the expression of PD-1 ligands on lymphoma cell lines","volume":"57","author":"Ma","year":"2017","journal-title":"JCEH"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"20852","DOI":"10.1073\/pnas.0810958105","article-title":"Oncogenic kinase NPM\/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)","volume":"105","author":"Marzec","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Liao, Z., Lv, X., Liu, S., He, Z., Chen, S., Wang, L., Li, W., and Li, Y. (2018). Different aberrant expression pattern of immune checkpoint receptors in patients with PTCL and NK\/T-CL. Asia Pac. J. Clin. Oncol.","DOI":"10.1111\/ajco.12850"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/nm.3394","article-title":"Microenvironmental regulation of tumor progression and metastasis","volume":"19","author":"Quail","year":"2013","journal-title":"Nat. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1111\/cas.13065","article-title":"An IL-27\/Stat3 axis induces expression of programmed cell death 1 ligands (PD-L1\/2) on infiltrating macrophages in lymphoma","volume":"107","author":"Horlad","year":"2016","journal-title":"Cancer Sci."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/nature24649","article-title":"PD-1 is a haploinsufficient suppressor of T cell lymphomagenesis","volume":"552","author":"Wartewig","year":"2017","journal-title":"Nature"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1182\/blood.V128.22.181.181","article-title":"Pembrolizumab for treatment of relapsed\/refractory mycosis fungoides and sezary syndrome: Clinical efficacy in a citn multicenter phase 2 study","volume":"128","author":"Khodadoust","year":"2016","journal-title":"Blood"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1182\/blood-2016-12-756841","article-title":"PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK\/T-cell lymphoma failing l-asparaginase","volume":"129","author":"Kwong","year":"2017","journal-title":"Blood"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in patients with relapsed or refractory hematologic malignancy: Preliminary results of a phase Ib study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1158\/1078-0432.CCR-16-1365","article-title":"Autologous T cells expressing CD30 chimeric antigen receptors for relapsed or refractory hodgkin lymphoma: An open-label phase I trial","volume":"23","author":"Wang","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1172\/JCI94306","article-title":"Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes","volume":"127","author":"Ramos","year":"2017","journal-title":"J. Clin. Investig."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1007\/s00277-016-2764-1","article-title":"Pembrolizumab for relapsed anaplastic large cell lymphoma after allogeneic haematopoietic stem cell transplantation: Efficacy and safety","volume":"95","author":"Chan","year":"2016","journal-title":"Ann. Hematol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"607","DOI":"10.7326\/L16-0037","article-title":"Nivolumab for refractory anaplastic large cell lymphoma: A case report","volume":"165","author":"Hebart","year":"2016","journal-title":"Ann. Intern. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"e26902","DOI":"10.1002\/pbc.26902","article-title":"Efficacy of nivolumab in a patient with systemic refractory ALK+ anaplastic large cell lymphoma","volume":"65","author":"Rigaud","year":"2018","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_86","first-page":"1116","article-title":"An anti-CD30 chimeric receptor that mediates CD3-zeta-independent T-cell activation against hodgkin\u2019s lymphoma cells in the presence of soluble cd30","volume":"58","author":"Hombach","year":"1998","journal-title":"Cancer Res."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1182\/blood-2006-11-059139","article-title":"Epstein barr virus specific cytotoxic T lymphocytes expressing the anti-cd30zeta artificial chimeric T-cell receptor for immunotherapy of hodgkin disease","volume":"110","author":"Savoldo","year":"2007","journal-title":"Blood"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1038\/sj.gt.3301467","article-title":"T cells engrafted with a recombinant anti-CD30 receptor target autologous CD30(+) cutaneous lymphoma cells","volume":"8","author":"Hombach","year":"2001","journal-title":"Gene Ther."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"6392","DOI":"10.1182\/blood-2009-03-209650","article-title":"T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a hodgkin tumor model","volume":"113","author":"Rooney","year":"2009","journal-title":"Blood"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1126\/science.1076514","article-title":"Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes","volume":"298","author":"Dudley","year":"2002","journal-title":"Science"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","article-title":"Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor","volume":"33","author":"Kochenderfer","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1172\/JCI40269","article-title":"Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice","volume":"120","author":"Ramakrishnan","year":"2010","journal-title":"J. Clin. Invest."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Turtle, C.J., Hanafi, L.A., Berger, C., Hudecek, M., Pender, B., Robinson, E., Hawkins, R., Chaney, C., Cherian, S., and Chen, X. (2016). Immunotherapy of non-hodgkin\u2019s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. Sci. Transl. Med., 8.","DOI":"10.1126\/scitranslmed.aaf8621"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1038\/leu.2017.57","article-title":"Fully human CD19-specific chimeric antigen receptors for T-cell therapy","volume":"31","author":"Sommermeyer","year":"2017","journal-title":"Leukemia"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/nature21405","article-title":"Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection","volume":"543","author":"Eyquem","year":"2017","journal-title":"Nature"},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Qasim, W., Zhan, H., Samarasinghe, S., Adams, S., Amrolia, P., Stafford, S., Butler, K., Rivat, C., Wright, G., and Somana, K. (2017). Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells. Sci. Transl. Med., 9.","DOI":"10.1126\/scitranslmed.aaj2013"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0022-1759(00)00228-3","article-title":"Immunophenotyping of leukemia","volume":"243","author":"Campana","year":"2000","journal-title":"J. Immunol. Methods"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/imr.12248","article-title":"Peripheral T-cell and NK cell lymphoproliferative disorders: Cell of origin, clinical and pathological implications","volume":"263","author":"Inghirami","year":"2015","journal-title":"Immunol. Rev."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1182\/blood-2017-01-761320","article-title":"CD7-edited T cells expressing a CD7-specific car for the therapy of T-cell malignancies","volume":"130","author":"Srinivasan","year":"2017","journal-title":"Blood"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1038\/s41375-018-0065-5","article-title":"An \u201coff-the-shelf\u201d fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies","volume":"32","author":"Cooper","year":"2018","journal-title":"Leukemia"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1038\/nm.4444","article-title":"Targeting the T cell receptor beta-chain constant region for immunotherapy of T cell malignancies","volume":"23","author":"Maciocia","year":"2017","journal-title":"Nat. Med."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/10\/9\/339\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:21:14Z","timestamp":1760196074000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/10\/9\/339"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,18]]},"references-count":101,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2018,9]]}},"alternative-id":["cancers10090339"],"URL":"https:\/\/doi.org\/10.3390\/cancers10090339","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,18]]}}}